Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Phase 2 Completed 24 enrolled Kubota Vision Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.

Timeline

Start: 2016-05
Primary completion: 2017-11
Completion: 2017-12

Outcome

Missed primary endpoint

paper Although this pilot study did not demonstrate statistically significant differences in changes in aqueous humor cytokine levels between the emixustat and placebo groups PMID 32852613 ↗

Publications

Kubota R, Jhaveri C, Koester JM, Gregory JK. Effects of emixustat hydrochloride in patients with proliferative diabetic retinopathy: a randomized, placebo-controlled phase 2 study. Graefes Arch Clin Exp Ophthalmol. 2021 Feb;259(2):369-378. doi: 10.1007/s00417-020-04899-y. Epub 2020 Aug 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Emixustat	Small molecule	40 mg	Oral